Crispr Therapeutics [CRSP] vs Regeneron [REGN] Detailed Stock Comparison
Crispr Therapeutics
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Crispr Therapeutics wins in 3 metrics, Regeneron wins in 14 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Crispr Therapeutics | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -15.61 | 15.13 | Crispr Therapeutics |
| Price-to-Book Ratio | 3.50 | 2.09 | Regeneron |
| Debt-to-Equity Ratio | 12.59 | 9.04 | Regeneron |
| PEG Ratio | -0.26 | -200.46 | Regeneron |
| EV/EBITDA | -10.65 | 12.86 | Crispr Therapeutics |
| Profit Margin (TTM) | -215.00% | 31.37% | Regeneron |
| Operating Margin (TTM) | -14,918.27% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | N/A | 29.64% | N/A |
| Return on Equity | -25.34% | 15.34% | Regeneron |
| Return on Assets (TTM) | -13.05% | 6.66% | Regeneron |
| Free Cash Flow (TTM) | $-144.68M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | 49.82% | -42.36% | Crispr Therapeutics |
| Price-to-Sales Ratio (TTM) | 161.92 | 4.47 | Regeneron |
| Enterprise Value | $4.66B | $57.45B | Regeneron |
| EV/Revenue Ratio | 122.34 | 4.04 | Regeneron |
| Gross Profit Margin (TTM) | N/A | 85.58% | N/A |
| Revenue per Share (TTM) | $0 | $133 | Regeneron |
| Earnings per Share (Diluted) | $-5.40 | $39.66 | Regeneron |
| Beta (Stock Volatility) | 1.84 | 0.31 | Regeneron |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Crispr Therapeutics vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Crispr Therapeutics | 3.62% | 10.07% | 29.74% | 37.12% | 116.77% | 69.42% |
| Regeneron | -2.42% | 4.41% | 4.84% | 8.80% | 2.22% | -18.14% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Crispr Therapeutics | 49.82% | 29.81% | -36.09% | 407.89% | 407.89% | 407.89% |
| Regeneron | -42.36% | -20.46% | -2.38% | 13.78% | 1,988.02% | 6,243.23% |
News Based Sentiment: Crispr Therapeutics vs Regeneron
Crispr Therapeutics
News based Sentiment: MIXED
October presented a mixed bag for CRISPR Therapeutics, with encouraging sales growth for Casgevy and promising pipeline developments offset by continued financial losses and a challenging earnings outlook. The company is making progress, but significant hurdles remain in achieving profitability and sustained growth.
Regeneron
News based Sentiment: POSITIVE
October proved to be a positive month for Regeneron, marked by key FDA approvals for Lynozyfic and Evkeeza, encouraging trial results for their obesity pipeline, and positive analyst coverage from JP Morgan and Morningstar. While the Eylea biosimilar settlement introduces a future challenge, the overall narrative points towards continued growth and potential value for investors.
Performance & Financial Health Analysis: Crispr Therapeutics vs Regeneron
| Metric | CRSP | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $6.24B | $63.78B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 2,514,739 | 1,129,150 |
| 90 Day Avg. Volume | 2,285,110 | 1,040,977 |
| Last Close | $70.19 | $585.48 |
| 52 Week Range | $30.04 - $73.95 | $476.49 - $1,024.36 |
| % from 52W High | -5.08% | -42.84% |
| All-Time High | $220.20 (Jan 11, 2021) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -68.12% | -51.66% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.73% | 0.04% |
| Quarterly Earnings Growth | N/A | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | -2.15% | 0.31% |
| Operating Margin (TTM) | -149.18% | 0.30% |
| Return on Equity (TTM) | -0.25% | 0.15% |
| Debt to Equity (MRQ) | 12.59 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.36 | $287.55 |
| Cash per Share (MRQ) | $18.93 | $72.04 |
| Operating Cash Flow (TTM) | $-324,771,008 | $4.74B |
| Levered Free Cash Flow (TTM) | $-239,332,128 | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Crispr Therapeutics vs Regeneron
| Metric | CRSP | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -15.61 | 15.13 |
| Forward P/E | -13.44 | 13.24 |
| PEG Ratio | -0.26 | -200.46 |
| Price to Sales (TTM) | 161.92 | 4.47 |
| Price to Book (MRQ) | 3.50 | 2.09 |
| Market Capitalization | ||
| Market Capitalization | $6.24B | $63.78B |
| Enterprise Value | $4.66B | $57.45B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 122.34 | 4.04 |
| Enterprise to EBITDA | -10.65 | 12.86 |
| Risk & Other Metrics | ||
| Beta | 1.84 | 0.31 |
| Book Value per Share (MRQ) | $19.36 | $287.55 |
Financial Statements Comparison: Crispr Therapeutics vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CRSP | REGN |
|---|---|---|
| Revenue/Sales | $0 | $3.03B |
| Cost of Goods Sold | $57.51M | $464.30M |
| Gross Profit | $-57.51M | $2.56B |
| Research & Development | $72.48M | $1.34B |
| Operating Income (EBIT) | $-148.42M | $591.70M |
| EBITDA | $-143.69M | $900.90M |
| Pre-Tax Income | $-134.89M | $905.00M |
| Income Tax | $1.11M | $96.30M |
| Net Income (Profit) | $-136.00M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CRSP | REGN |
|---|---|---|
| Cash & Equivalents | $235.18M | $3.09B |
| Total Current Assets | $1.87B | $17.57B |
| Total Current Liabilities | $119.45M | $3.57B |
| Long-Term Debt | $201.85M | $2.70B |
| Total Shareholders Equity | $1.83B | $29.39B |
| Retained Earnings | $-1.50B | $32.38B |
| Property, Plant & Equipment | $182.48M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CRSP | REGN |
|---|---|---|
| Operating Cash Flow | $-96.31M | $1.36B |
| Capital Expenditures | $-206,000 | N/A |
| Free Cash Flow | $-54.15M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | CRSP | REGN |
|---|---|---|
| Shares Short | 23.81M | 2.99M |
| Short Ratio | 12.64 | 3.06 |
| Short % of Float | 0.30% | 0.03% |
| Average Daily Volume (10 Day) | 2,514,739 | 1,129,150 |
| Average Daily Volume (90 Day) | 2,285,110 | 1,040,977 |
| Shares Outstanding | 85.74M | 109.62M |
| Float Shares | 90.51M | 97.89M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 0.81% | 0.90% |
Dividend Analysis & Yield Comparison: Crispr Therapeutics vs Regeneron
| Metric | CRSP | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |